MADOULET CLAUDINE,마둘렛, 클라우딘,TOSI PIERRE FRANCOIS,토시, 피에르-프랑수아,NICOLAU CLAUDE,니꼴라우, 클라우데,HICKMAN DAVID T.,힉크만, 데이비드 티.
申请号：
KR1020127033292
公开号：
KR1020130008092A
申请日:
2004.07.25
申请国别(地区):
KR
年份:
2013
代理人:
摘要：
Immunogenic composition (A) comprising a vehicle and as antigenic structure, a conjugate (I) of at least one peptide (Ia) derived from extracellular loop 1 of protein P-170, where each (Ia) is associated with several molecules (Ib) of fatty acid of chain length 12-24C is new. Immunogenic composition (A) comprising a vehicle and as antigenic structure, a conjugate (I) of at least one peptide (Ia) derived from extracellular loop 1 of protein P-170, where each (Ia) is associated with several molecules (Ib) of fatty acid of chain length 12-24C is new. (I) displays at least part of the conformation of the loop for inducing anti-P-107 antibodies (Ab) or for causing reversal of multidrug resistance in cancer patients. ACTIVITY : Cytostatic. The tetrapalmitoylated peptide Lys-Gly-Gly-Asn-Met-Thr-Asp-Ser-Phe-Thr-Lys-Ala-Glu-Ala-Ser-Ile-Leu-Pro-Ser-Ile-Thr-Asn-Gln-Gly-Pro-Asn-Ser-Thr-Leu-Ile-Ile-Ser-Asn-Ser-Ser-Leu-(Glu) 3-Gly-Lys-Lys-NH 2 was formulated in liposomes (mole ratio peptide:lipids 1:250) and administered three times to mice at intervals of 2 weeks, at doses of 0.2 ml. The animals were then inoculated (day 0) with1 million P388R chemoresistant cells and treated with 5.5 mg/kg doxorubicin (days 1, 10 and 21) and 2.5 mg/kg vinblastine (days 4 and 14). The mean survival time was 39 days； compare 22 days for animals injected with empty liposomes. MECHANISM OF ACTION : Vaccine； inhibtion of P-170 which is responsible for expulsion of chemotherapeutic agents from cells.본 발명의 목적은 담체 및 항원성 구조로 컨쥬게이트를 포함하고, 상기 컨쥬게이트는 P-170 단백질의 세포외 루프로부터 유래된 적어도 하나의 펩타이드를 포함하는 것을 특징으로 하는 면역성 조성물이다. 각 펩타이드는 적당한 투여 조건 하에 항-P-170 항체의 유도를 허여하기 위하여 C12 내지 C24 사이의 탄소 사슬을 함유하는 몇개의 지방산 분자와 결합한다. 본 발명은 다중약물 내성 치료 수단을 명확히 하기 위한 상기 조성물에 관한 것이다.
